- Home
- PINS vs BIIB Comparison
PINS vs BIIB Comparison
Compare PINS & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PINS
- BIIB
- Stock Information
- Founded
- PINS 2008
- BIIB 1978
- Country
- PINS United States
- BIIB United States
- Employees
- PINS N/A
- BIIB N/A
- Industry
- PINS Computer Software: Programming Data Processing
- BIIB Biotechnology: Pharmaceutical Preparations
- Sector
- PINS Technology
- BIIB Health Care
- Exchange
- PINS Nasdaq
- BIIB Nasdaq
- Market Cap
- PINS 19.9B
- BIIB 18.8B
- IPO Year
- PINS 2019
- BIIB 1991
- Fundamental
- Price
- PINS $35.69
- BIIB $130.43
- Analyst Decision
- PINS Buy
- BIIB Buy
- Analyst Count
- PINS 29
- BIIB 27
- Target Price
- PINS $40.68
- BIIB $188.17
- AVG Volume (30 Days)
- PINS 9.7M
- BIIB 1.3M
- Earning Date
- PINS 07-29-2025
- BIIB 07-31-2025
- Dividend Yield
- PINS N/A
- BIIB N/A
- EPS Growth
- PINS 1137.45
- BIIB 26.39
- EPS
- PINS 2.71
- BIIB 10.12
- Revenue
- PINS $3,761,171,000.00
- BIIB $9,816,400,000.00
- Revenue This Year
- PINS $16.37
- BIIB N/A
- Revenue Next Year
- PINS $15.44
- BIIB N/A
- P/E Ratio
- PINS $13.19
- BIIB $12.85
- Revenue Growth
- PINS 17.81
- BIIB 1.59
- 52 Week Low
- PINS $23.68
- BIIB $110.04
- 52 Week High
- PINS $44.06
- BIIB $238.00
- Technical
- Relative Strength Index (RSI)
- PINS 62.69
- BIIB 44.72
- Support Level
- PINS $34.22
- BIIB $123.90
- Resistance Level
- PINS $36.25
- BIIB $129.27
- Average True Range (ATR)
- PINS 0.96
- BIIB 2.85
- MACD
- PINS -0.03
- BIIB -0.66
- Stochastic Oscillator
- PINS 76.12
- BIIB 19.77
About PINS Pinterest Inc.
Pinterest is a social media platform with a focus on product and idea discovery. Pinterest users, or pinners, can leverage the platform as they go about gathering ideas on topics such as home improvement, fashion, cooking, and travel. The company has more than 500 million monthly active users, two thirds of whom are female. Pinterest generates revenue by selling digital ads on its platform. While the platform's user base spans the globe, the vast majority of its revenue stems from ads shown to North American users.
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.